Atreca to Present Immuno-Oncology Research Findings at 2018 World Preclinical Congress
“The power of our IRC™ technology lies in its ability to accurately discover anti-tumor antibodies in patients who have achieved successful outcomes following anti-cancer treatments, such as checkpoint inhibitor immunotherapy,” said John A. Orwin, Atreca’s President and Chief Executive Officer. “As highlighted in this promising research, our recombinantly expressed antibodies were able to cause tumor regression and induce durable immunity in in vivo preclinical cancer models. We are delighted to report on the progress of this and other key research at Atreca as we continue to advance our pipeline toward entry into the clinic next year.”
Details regarding the oral presentation are available on the WPC website and are also as follows:
Presentation Title: Discovery and Characterization of Functional Anti-Tumor Antibodies from Non-Progressing Cancer Patients Undergoing Immunotherapy
- Session Title: New Targets and Approaches; Preclinical Strategies, Models & Tools in Oncology: Executive Summit
- Presentation Date & Time: Tuesday, June 19, 2018, 11:05 AM ET
- Location: Essex South Room, Westin Copley Place
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors (TCRs), and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® (IRC™) technology profiles a patient’s immune response at the single-cell level at very high throughput essentially without bias or error. This approach enables the identification, generation, and analysis of functional human antibody and TCR sequences from single B and T cells without prior knowledge of antigen. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.
Source: Atreca, Inc.